scholarly journals Edmonton Obesity Staging System Prevalence and Association with Weight Loss in a Publicly Funded Referral-Based Obesity Clinic

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Karissa L. Canning ◽  
Ruth E. Brown ◽  
Sean Wharton ◽  
Arya M. Sharma ◽  
Jennifer L. Kuk
Keyword(s):  
Risk Factors ◽  
Weight Loss ◽  
Weight Management ◽  
Treatment Time ◽  
Staging System ◽  
Publicly Funded ◽  
Weight Outcomes ◽  
Psychological Comorbidities ◽  
Similar Weight ◽  
Edmonton Obesity Staging System

Objectives. To determine the distribution of EOSS stages and differences in weight loss achieved according to EOSS stage, in patients attending a referral-based publically funded multisite weight management clinic.Subjects/Methods. 5,787 obese patients were categorized using EOSS staging using metabolic risk factors, medication use, and severity of doctor diagnosis of obesity-related physiological, functional, and psychological comorbidities from electronic patient files.Results. The prevalence of EOSS stages 0 (no risk factors or comorbidities), 1 (mild conditions), 2 (moderate conditions), and 3 (severe conditions) was 1.7%, 10.4%, 84.0%, and 3.9%, respectively. Prehypertension (63%), hypertension (76%), and knee replacement (33%) were the most common obesity-related comorbidities for stages 1, 2, and 3, respectively. In the models including age, sex, initial BMI, EOSS stage, and treatment time, lower EOSS stage and longer treatment times were independently associated with greater absolute (kg) and percentage of weight loss relative to initial body weightP<0.05.Conclusions. Patients attending this publicly funded, referral-based weight management clinic were more likely to be classified in the higher stages of EOSS. Patients in higher EOSS stages required longer treatment times to achieve similar weight outcomes as those in lower EOSS stages.

Edmonton Obesity Staging System Prevalence in the Wharton Medical Clinic and the Association with Weight Loss

2013 ◽  
Vol 37 ◽  
pp. S255
Author(s):  
Karissa Canning ◽  
Ruth E. Brown ◽  
Sean Wharton ◽  
Arya M. Sharma ◽  
Jennifer L. Kuk
Keyword(s):  
Weight Loss ◽  
Staging System ◽  
Medical Clinic ◽  
Edmonton Obesity Staging System ◽  
Obesity Staging

scholarly journals Effect of a Six-Month Weight Loss Program on The Scores of The Edmonton Obesity Staging System

2013 ◽  
Vol 37 ◽  
pp. S281-S282
Author(s):  
Marcela Rodriguez-Flores ◽  
Teresa Cuatecontzi-Xochitiotzi ◽  
Veronica Vazquez-Velazquez ◽  
Eduardo García-García
Keyword(s):  
Weight Loss ◽  
Staging System ◽  
Weight Loss Program ◽  
Edmonton Obesity Staging System ◽  
Obesity Staging

scholarly journals Adherence to a Plant-Based Diet and Consumption of Specific Plant Foods—Associations with 3-Year Weight-Loss Maintenance and Cardiometabolic Risk Factors: A Secondary Analysis of the PREVIEW Intervention Study

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3916
Author(s):  
Ruixin Zhu ◽  
Mikael Fogelholm ◽  
Sally D. Poppitt ◽  
Marta P. Silvestre ◽  
Grith Møller ◽  
...  
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Weight Loss ◽  
Weight Management ◽  
Cardiometabolic Risk ◽  
Ldl Cholesterol ◽  
Secondary Analysis ◽  
Weight Loss Maintenance ◽  
Cardiometabolic Risk Factors ◽  
Plant Foods

Plant-based diets are recommended by dietary guidelines. This secondary analysis aimed to assess longitudinal associations of an overall plant-based diet and specific plant foods with weight-loss maintenance and cardiometabolic risk factors. Longitudinal data on 710 participants (aged 26–70 years) with overweight or obesity and pre-diabetes from the 3-year weight-loss maintenance phase of the PREVIEW intervention were analyzed. Adherence to an overall plant-based diet was evaluated using a novel plant-based diet index, where all plant-based foods received positive scores and all animal-based foods received negative scores. After adjustment for potential confounders, linear mixed models with repeated measures showed that the plant-based diet index was inversely associated with weight regain, but not with cardiometabolic risk factors. Nut intake was inversely associated with regain of weight and fat mass and increments in total cholesterol and LDL cholesterol. Fruit intake was inversely associated with increments in diastolic blood pressure, total cholesterol, and LDL cholesterol. Vegetable intake was inversely associated with an increment in diastolic blood pressure and triglycerides and was positively associated with an increase in HDL cholesterol. All reported associations with cardiometabolic risk factors were independent of weight change. Long-term consumption of nuts, fruits, and vegetables may be beneficial for weight management and cardiometabolic health, whereas an overall plant-based diet may improve weight management only.

scholarly journals Receptivity to Bariatric Surgery in Qualified Patients

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Michael Fung ◽  
Sean Wharton ◽  
Alison Macpherson ◽  
Jennifer L. Kuk
Keyword(s):  
Social Support ◽  
Bariatric Surgery ◽  
Weight Loss ◽  
Weight Management ◽  
Diabetes Management ◽  
Effective Intervention ◽  
Publicly Funded ◽  
Factors Influencing ◽  
Positive Social Support ◽  
Weight Loss Success

Objectives. Bariatric surgery has been shown to be an effective intervention for weight loss and diabetes management. Despite this, many patients qualified for bariatric surgery are not interested in undergoing the procedure. The objective of this study is to determine the factors influencing receptivity to bariatric surgery among those who qualify for the procedure.Methods. Patients attending a publicly funded weight management clinic who qualified for bariatric surgery were asked to complete an elective questionnaire between February 2013 and April 2014.Results. A total of 371 patients (72% female) completed the questionnaire. Only 87 of 371 (23%) participants were interested in bariatric surgery. Individuals interested in bariatric surgery had a higher BMI (48.0 versus 46.2 kg/m2,P=0.03) and believed that they would lose more weight with surgery (51 versus 44 kg,P=0.0069). Those who scored highly on past weight loss success and financial concerns were less likely to be interested in bariatric surgery, whereas those who scored highly on high receptivity to surgery and positive social support were more likely to be interested in bariatric surgery.Conclusion. Although participants overestimated the effect of bariatric surgery on weight loss, most were still not interested in bariatric surgery.

scholarly journals Predictors of Weight Loss and Weight Gain in Weight Management Patients during the COVID-19 Pandemic

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Jennifer L. Kuk ◽  
Rebecca A. G. Christensen ◽  
Elham Kamran Samani ◽  
Sean Wharton
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Weight Gain ◽  
Weight Management ◽  
Management Program ◽  
Publicly Funded ◽  
Electronic Survey ◽  
Survey Results ◽  
Predictors Of Weight Loss ◽  
Management Changes

Objective. To examine the associations between patient struggles, health, and weight management changes during the COVID-19 pandemic. Methods. 585 patients attending a publicly funded clinical weight management program responded to an electronic survey. Results. Over half of the patients reported worsened overall health, mental health, physical activity, or diet during the pandemic. Approximately 30% of patients lost ≥3% of their body weight and 21% gained ≥3% of their body weight between March and July of the pandemic. Reports of social isolation was associated with increased odds for weight loss in women (OR = 2.0, 1.2–3.3), while low motivation (OR = 1.9, 1.0–3.7), depression (OR = 2.5, 1.0–6.3), and struggles with carbohydrate intake (OR = 2.1, 1.0–4.3) were associated with weight gain. Cooking more at home/eating less take out was associated with increased likelihood of weight loss (OR = 2.1, 1.1–3.9) and lower odds for weight gain (OR = 0.2, 0.1 to 0.97). Working from home was not associated with weight loss or weight gain ( P > 0.6 ). Conclusion. The COVID-19 pandemic is associated with certain factors that may facilitate weight loss and other factors that promote weight gain. Thus, depending on the patient experience during the pandemic, prevention of weight gain may be more appropriate than weight loss.

Difference in weight loss based on ethnicity, age and comorbidity status in a publicly funded adult weight management centre: 1-year results

2013 ◽  
Vol 3 (1-2) ◽  
pp. 21-31 ◽  
Author(s):  
R. H. Liu ◽  
S. Wharton ◽  
A. M. Sharma ◽  
C. I. Ardern ◽  
J. L. Kuk
Keyword(s):  
Weight Loss ◽  
Weight Management ◽  
Publicly Funded ◽  
Adult Weight ◽  
Comorbidity Status

scholarly journals Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A10-A10
Author(s):  
John P H Wilding ◽  
Rachel L Batterham ◽  
Salvatore Calanna ◽  
Melanie Davies ◽  
Luc F Van Gaal ◽  
...  
Keyword(s):  
Risk Factors ◽  
Weight Loss ◽  
Body Weight ◽  
Weight Management ◽  
Treatment Adherence ◽  
Weight Change ◽  
Cardiometabolic Risk ◽  
Body Weight Change ◽  
Efficacy And Safety ◽  
Overweight Or Obesity

Abstract Background: Despite the increasing global adverse health impact of obesity, there are few pharmacological options for effective weight management. STEP 1 investigated the efficacy and safety of the glucagon-like peptide-1 analogue, subcutaneous (s.c.) semaglutide, for weight management in adults with overweight or obesity. Methods: This randomized, double-blind, placebo-controlled, phase 3 trial was conducted at 129 sites across 16 countries (NCT03548935). Adults aged ≥18 years with either body mass index (BMI) ≥30 kg/m2 or BMI ≥27 kg/m2 with ≥1 weight-related comorbidity, without type 2 diabetes, were randomized 2:1 to 68 weeks’ treatment with once-weekly s.c. semaglutide 2.4 mg or placebo, both as adjunct to lifestyle intervention. The co-primary endpoints were percentage change in body weight and achievement of weight loss ≥5%. Cardiometabolic risk factors, patient-reported outcomes, and safety/tolerability were also assessed. Two estimands were defined: treatment policy (effect regardless of treatment adherence and use of rescue intervention) and trial product (effect assuming treatment adherence and without rescue intervention); results are presented for the treatment policy estimand, unless stated otherwise. P values for parameters marked with # were not controlled for multiplicity. Results: 1961 randomized participants (mean age 46 years, body weight 105.3 kg, BMI 37.9 kg/m2; 74.1% female) were included. Mean body weight change from baseline to week 68 was −14.9% in the semaglutide group vs −2.4% with placebo (estimated treatment difference [ETD]: −12.4%; 95% confidence interval (CI): −13.4, −11.5; p&lt;0.0001). Similar results were obtained with the trial product estimand: mean body weight change# was -16.9% for semaglutide vs -2.4% for placebo (ETD: -14.4%; 95% CI: -15.3, -13.6; p&lt;0.0001). Participants were more likely to achieve weight loss ≥5%, ≥10%, ≥15%, and ≥20%# with semaglutide vs placebo (86.4% vs 31.5%, 69.1% vs 12.0%, 50.5% vs 4.9%, and 32.0% vs 1.7%, respectively; p&lt;0.0001 for all). Greater improvements were seen with semaglutide vs placebo in waist circumference, BMI#, systolic and diastolic# blood pressure, glycated hemoglobin#, fasting plasma glucose#, C-reactive protein#, fasting lipid profile#, and self-reported physical functioning (p&lt;0.05 for all). No new safety signals with semaglutide were observed. The most frequent adverse events with semaglutide were gastrointestinal disorders (typically transient and mild-to-moderate). Conclusion: In adults with overweight or obesity, once-weekly s.c. semaglutide 2.4 mg plus lifestyle intervention induced a mean weight loss of approximately 15% by week 68. Clinically beneficial weight loss of ≥10% was achieved by over two-thirds of participants and ≥20% by one-third of participants, along with associated improvements in cardiometabolic risk factors and physical functioning.

scholarly journals Class 3 Obesity in a Multidisciplinary Metabolic Weight Management Program: The Effect of Preexisting Type 2 Diabetes on 6-Month Weight Loss

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
David M. Medveczky ◽  
Raymond Kodsi ◽  
Kathryn Skelsey ◽  
Kathy Grudzinskas ◽  
Flavia Bueno ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Weight Management ◽  
Management Program ◽  
Publicly Funded ◽  
Percentage Weight ◽  
Weight Loss Outcomes ◽  
Potential Weight ◽  
Hospital Clinic

Introduction. Class 3 obesity (BMI≥40 kg/m2) is a growing health problem worldwide associated with considerable comorbidity including Type 2 diabetes mellitus (T2DM). The multidisciplinary medical management of obesity can be difficult in T2DM due to potential weight gain from medications including sulphonylureas and insulin. However, newer weight-neutral/losing diabetes medications can aid additional weight loss. The aim of this study was to compare weight loss outcomes of patients with and without T2DM, and in patients with T2DM, to compare diabetes outcomes and change in medications at 6 months. Methods. All patients entering a multidisciplinary weight management metabolic program in a publicly funded hospital clinic in Sydney between March 2018 and March 2019, with BMI≥40 kg/m2 and aged ≥18 years were included. Data was collected from patient clinical and electronic notes at baseline and 6 months. Results. Of the 180 patients who entered the program, 53.3% had T2DM at baseline. There was no difference in percentage weight loss in those with or without T2DM (4.2±4.9% vs. 3.6±4.7%, p=0.35). Additionally, T2DM patients benefited from a 0.47% reduction in HbA1c (p<0.01) and a reduction in the number of medications from baseline to 6 months (1.8±1.0/patient vs. 1.0±1.2/patient, p<0.001). T2DM patients who started on weigh-neutral/losing medications in the program lost more weight than those started on weight-gaining medications (7.7±5.3% vs. 2.4±3.8%, p=0.015). Conclusions. Patients with class 3 obesity had significant weight loss at 6 months in this program. Patients with T2DM at baseline had comparable weight loss at 6 months, a significant improvement in glycaemic control, and a reduction in diabetes medication load. Additionally, patients with T2DM who were started on weight-neutral/losing medications lost significantly more weight than those started on weight-gaining medications, and these medications should be preferentially used in class 3 obesity and comorbid T2DM.

Sign in / Sign up

Export Citation Format

Share Document